207 related articles for article (PubMed ID: 35524725)
21. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
22. Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.
Wang SS; Pandey K; Watson KA; Abbott RC; Mifsud NA; Gracey FM; Ramarathinam SH; Cross RS; Purcell AW; Jenkins MR
Mol Ther Oncolytics; 2023 Sep; 30():167-180. PubMed ID: 37674626
[TBL] [Abstract][Full Text] [Related]
23. Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.
Patel SK; Hartley RM; Wei X; Furnish R; Escobar-Riquelme F; Bear H; Choi K; Fuller C; Phoenix TN
Neuro Oncol; 2020 Mar; 22(3):381-392. PubMed ID: 31638150
[TBL] [Abstract][Full Text] [Related]
24. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
[TBL] [Abstract][Full Text] [Related]
25. Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma.
Sharma M; Barravecchia I; Magnuson B; Ferris SF; Apfelbaum A; Mbah NE; Cruz J; Krishnamoorthy V; Teis R; Kauss M; Koschmann C; Lyssiotis CA; Ljungman M; Galban S
Neoplasia; 2023 Oct; 44():100931. PubMed ID: 37647805
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy and radio-sensitization in H3
Liu C; Kuang S; Wu L; Cheng Q; Gong X; Wu J; Zhang L
CNS Neurosci Ther; 2023 Jul; 29(7):1721-1737. PubMed ID: 37157237
[TBL] [Abstract][Full Text] [Related]
27. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
[TBL] [Abstract][Full Text] [Related]
28. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
[TBL] [Abstract][Full Text] [Related]
29. PRC2-independent actions of H3.3K27M in embryonic stem cell differentiation.
Cohen LRZ; Kaffe B; Deri E; Leibson C; Nissim-Rafinia M; Maman M; Harpaz N; Ron G; Shema E; Meshorer E
Nucleic Acids Res; 2023 Feb; 51(4):1662-1673. PubMed ID: 36156096
[TBL] [Abstract][Full Text] [Related]
30. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
32. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
[TBL] [Abstract][Full Text] [Related]
33. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Grassl N; Sahm K; Süße H; Poschke I; Bunse L; Bunse T; Boschert T; Mildenberger I; Rupp AK; Ewinger MP; Lanz LM; Denk M; Tabatabai G; Ronellenfitsch MW; Herrlinger U; Glas M; Krex D; Vajkoczy P; Wick A; Harting I; Sahm F; von Deimling A; Bendszus M; Wick W; Platten M
Neurol Res Pract; 2023 Oct; 5(1):55. PubMed ID: 37853454
[TBL] [Abstract][Full Text] [Related]
34. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
[TBL] [Abstract][Full Text] [Related]
35. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
36. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
38. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
Anderson JL; Muraleedharan R; Oatman N; Klotter A; Sengupta S; Waclaw RR; Wu J; Drissi R; Miles L; Raabe EH; Weirauch ML; Fouladi M; Chow LM; Hoffman L; DeWire M; Dasgupta B
Neuro Oncol; 2017 Aug; 19(8):1068-1078. PubMed ID: 28339768
[TBL] [Abstract][Full Text] [Related]
39. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
40. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
